Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations

Neurochemical Research

Volumn 23, Issue 12, 1998, Pages 1521-1525

  Loeffler, D A ^a   LeWitt, P A ^a,b   Juneau, P L ^a   Camp, D M ^a   DeMaggio, A J ^a   Havaich, M K ^a   Milbury, P E ^c   Matson, W R ^c  

^a SINAI GRACE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ESA Biosciences Inc   (United States)

Author keywords

Cerebrospinal fluid; Dopamine; Levodopa; Parkinson's disease; Serotonin; Striatum

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; CARBIDOPA; LEVODOPA; SEROTONIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031738590     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020923919560     Document Type: Article

References (49)

1. Fahn, S., Libsch, L.R., and Cutler, R.W. 1971. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. neurol. Sci. 14:427-455.
2. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y. 1983. Reduction of cortical dopamine, noradenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275:321-328.
3. Javoy-Agid, F., Ruberg, M., Taquet, H., Bokobza, B., Agid, Y., Gaspar, P., Berger, B., N'Guyen-Legros, J., Alvarez, C., Gray, F., Escourolle, R., Scatton, B. and Rouquier, L. 1984. Biochemical neuropathology of Parkinson's disease. Adv. Neurol. 40:189-198.
4. Halliday, G.M., Blumbergs, P.C., Cotton, R.G.H., Blessing, W.W. and Geffen, L.B. 1990. Loss of brainsteam serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510:104-107.
5. Van Praag, H.M. and de Haan, S. 1979. Central serotonin metabolism and frequency of depression. Psychiatr. Res. 1:219-224.
6. Mayeux, R. 1990. The "serotonin hypothesis" for depression in Parkinson's disease. Adv. Neurol. 53:163-166.
7. Melamed, E., Zoldan, J., Friedberg, G., Ziv, I., and Weizmann, A. 1996. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-dopa therapy. Adv. Neurol. 69:545-550.
8. Chase, T.N., Ng, L.K.Y., and August, M. 1972. Parkinson's disease: modification by 5-hydroxytrytophan. Neurology 22:479-484.
9. Sano, U.I. and Taniguchi, K. 1972. L-5-hydroxytryptophan (L-5-HTP) therapie des morbus parkinson. Munch. Med. Wochenschr. 114:1717-1719.
10. Mayeux, R., Stern, Y., Williams, J.B.W., Sano, M., and Cote, L. 1986. Depression and Parkinson's disease. Adv. Neurol. 45:451-455.
11. McCance-Katz, E.F., Marek, K.L., and Price, L.H. 1993. Serotonin, depression, and PD [letter]. Neurology 43:1625.
12. Steur, E.N. 1993. Increase of Parkinson disability after fluoxetine medication. Neurology 43:211-213.
13. Schmidt, C.J., Black, C.K., Taylor, V.L., Fadayel, G.M., Humphreys, T.M., Nieduzak, T.R., and Sorenson, S.M. 1992. The 5-HT2 receptor antagonist, MDL 28, 133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 220:151-159.
14. Herz, A. and Zieglgansberger, W. 1968. The influence of microelectrophoretically applied biogenic amines, cholinomimetics and procaine on synaptic excitation in the corpus striatum. Int. J. Neuropharmacol. 7:221-230.
15. Fibiger, H.C. and Miller, J.J. 1977. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2:975-987.
16. Davies, J. and Tongroach, P. 1978. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur. J. Pharmacol. 51:91-100.
17. VanderMaelen, C.P., Bonduki, A.C., and Kitai, S.T. 1979. Excitation of caudate-putamen neurons following stimulation of the dorsal raphe nucleus in the rat. Brain Res. 175:356-361.
18. Park, M.R., Gonzales-Vegas, J.A., and Kitai, S.T. 1982. Serotonergic excitation from dorsal raphe stimulation recorded intracellularly from rat caudate-putamen. Brain Res. 243:49-58.
19. Stefani, A., Surmeier, D.J., and Kitai, S.T. 1990. Serotonin enhances excitability in neostriatal neurons by reducing voltage-dependent potassium currents. Brain Res. 529:354-357.
20. Yakel, J.L., Trussell, L.O., and Jackson, M.B. 1988. Three serotonin responses in cultured mouse hippocampal and striatal neurons. J. Neurosci. 8:1273-1285.
21. Rinne, U.K., Sonninen, V., Riekkinen, P., and Laaksonen, H. 1974. Dopaminergic nervous transmission in Parkinson's disease. Med. Biol. 52:208-217.
22. Bartholini, G., Da Prada, M., and Pletscher, A. 1968. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol. 20:229-230.
23. Butcher, L.L. and Engel, J. 1969. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition. Brain Res. 14:233-242.
24. Everett, G.M. and Borcherding, J.W. 1970. L-dopa: effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. Science 168:849-850.
25. Fahn, S., Snider, S. Prasad, A.L.N., Lane, E., and Makadon, H. 1975. Normalization of brain serotonin by L-tryptophan in levodopa treated rats. Neurology 25:861-865.
26. Nausieda, P.A., Tanner, C.M., and Klawans, H.L. 1983. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv. Neurol. 37:23-32.
27. Jenner, P., Sheehy, M., and Marsden, C.D. 1983. Noradrenaline and 5-hydroxytryptamine modulation of brain function: implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol. 15 [Suppl 2]:277S-289S.
28. Hashiguti, H., Nakahara, D., Maruyama, W., Naoi, M., and Ikeda, T. 1993. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J. Neural Transm. [Genl. Sect.] 93:213-223.
29. Arai, R., Karasawa, N., Geffard, M., and Nagatsu, I. 1995. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195:195-198.
30. Ng, K.Y., Colburn, R.W., and Kopin, I.J. 1971. Effects of L- dopa on efflux of cerebral monoamines from synaptosomes. Nature 230: 331-332.
31. Fernstrom, J.D. and Wurtman, R.J. 1972. Brain serotonin content: Physiological regulation by plasma neutral amino acids. Science 178:414-416.
32. Molinengo, L., Scordo, I., Pastorello, B., Orsetti, M., and Ghi, P. 1996. Behavioral and neurochemical effects induced by chronic L-dopa administration. Pharmacol. Biochem. Behav. 54:779-785.
33. Bivin, W.S. and Smith, G.D. 1984. Techniques of experimentation. Pages 585-586, in Fox, J.G., Cohen, B.J., and Loew, F.M. (eds), Laboratory Animal Medicine, Academic Press, Orlando.
34. Loeffler, D.A., DeMaggio, A.J., Juneau, P.L., Havaich, M.K., and LeWitt, P.A. 1994. Effects of enhanced striatal dopamine turnover in vivo on glutathione production. Clin. Neuropharmacol. 17:370-379.
35. Beal, M.F., Matson, W.R., Swartz, K.J., Gamache, P.H., and Bird E.D. 1990. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 55:1327-1339.
36. Cleveland, W.S. 1993. Pages 25-27, in Visualizing Data, Hobart Press, Summit.
37. SAS Institute, Inc. 1986. Page 533, in: SUGI Supplemental User's Guide, Version 5 edition, SAS Institute, Inc., Cary.
38. Spencer, S.E. and Wooten, G.F. 1984. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervalion. Neurology 34:1105-1108.
39. Melamed, E., Globus, M., Friedlender, E., and Rosenthal, J. 1983. Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections. Neurology 33:950-953.
40. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J. and Hamato, H. 1993. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci. Lett. 159:135-138.
41. Jacobs, B.L. and Azmitia, E.L. 1992. Structure and function of the brain serotonin system. Physiol. Rev. 72:165-229.
42. Wester, P., Bergstrom, U., Eriksson, A., Gezelius, C., Hardy, J., and Winblad, B. 1990. Ventricular cerebrospinal fluid monoamine neurotransmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J. Neurochem. 54:1148-1156.
43. Martin, D.C., Introna, R.P., and Aronstam, R.S. 1990. Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter. Neurosci. Lett. 112:99-103.
44. Tao, R. and Auerbach, S.B. 1994. Anesthetics block morphine-induced increases in serotonin release in rat CNS. Synapse 18: 307-314.
45. Zhou, F.C., Bledsoe, S., and Murphy, J. 1991. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556:108-116.
46. Takeuchi, Y., Sawada, T., Blunt, S., Jenner, P., and Marsden, C.D. 1991. Effects of 6-hydroxydopamine lesions of the nigrostriatal pathway on striatal serotonin innervation in adult rats. Brain Res. 562:301-305.
47. Kaerstadt, P.J., Kerasidis, H., Pincus, J.H., Meloni, R., Graham, J., and Gale, K. 1994. Unilateral destruction of dopamine pathways increases ipsalateral striatal serotonin turnover in rats. Exp. Neurol. 126:25-30.
48. Oreland, L., Arai, Y., Stenstrom, A., and Fowler, C.J. 1983. Monoamine oxidase activity and localization in the brain and the activity in relation to psychiatric disorders. Psychiat. Res. 4:21-29.
49. Maker, H.S. 1983. Glutathione. Pages 607-631 in A. Lajtha (ed.), Handbook of Neurochemistry, 2nd ed., Vol. 3, Plenum Press, New York.